Mutations Found in embCAB, embR, and ubiA Genes of Ethambutol-Sensitive and -Resistant Mycobacterium tuberculosis Clinical Isolates from China

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Xu, Yuhui ^a   Jia, Hongyan ^a   Huang, Hairong ^a   Sun, Zhaogang ^a   Zhang, Zongde ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; CODON; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; DRUG EFFECTS; GENETICS; HUMAN; MICROBIOLOGY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CHINA; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; GENES, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84941662583     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/951706     Document Type: Article

References (38)

1. American Thoracic Society, CDC, and Infectious Diseases Society of America, "Treatment of tuberculosis," Morbidity and Mortality Weekly Report-Recommendations and Reports, vol. 52, no. RR11, pp. 1-77, 2003.
2. A. Y. Coban, A. Deveci, A. T. Sunter, and A. Martin, "Nitrate reductase assay for rapid detection of isoniazid, rifampin, ethambutol, and streptomycin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis," Journal of Clinical Microbiology, vol. 52, no. 1, pp. 15-19, 2014.
3. Y. Feng, S. Liu, Q. Wang et al., "Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl Assay: a metaanalysis," PLoS ONE, vol. 8, no. 2, Article ID e55292, 2013.
4. H. Safi, S. Lingaraju, A. Amin et al., "Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-Arabinose biosynthetic and utilization pathway genes," Nature Genetics, vol. 45, no. 10, pp. 1190-1197, 2013.
5. E. Radmacher, K. C. Stansen, G. S. Besra et al., "Ethambutol, a cell wall inhibitor of Mycobacterium tuberculosis, elicits Lglutamate efflux of Corynebacterium glutamicum," Microbiology, vol. 151, no. 5, pp. 1359-1368, 2005.
6. Y. F. Yen,M. S. Chung,H. Y.Huet al., "Associationof pulmonary tuberculosis and ethambutol with incident depressive disorder: a nationwide, population-based cohort study," Journal of Clinical Psychiatry, vol. 76, no. 4, pp. 505-511, 2015.
7. S. Sreevatsan, K. E. Stockbauer, X. Pan et al., "Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations," Antimicrobial Agents and Chemotherapy, vol. 41,no. 8, pp. 1677-1681, 1997.
8. Y. Xu, Z. Zhang, and Z. Sun, "Drug resistance to Mycobacterium tuberculosis: from the traditional Chinese view to modern systems biology," Critical Reviews in Microbiology, vol. 41, no. 3, pp. 399-410, 2015.
9. C. Plinke, H. S. Cox, N. Zarkua et al., "embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation," Journal of Antimicrobial Chemotherapy, vol. 65, no. 7, Article ID dkq120, pp. 1359-1367, 2010.
10. H. Safi, R. D. Fleischmann, S. N. Peterson, M. B. Jones, B. Jarrahi, and D. Alland, "Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis," Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 103-108, 2010.
11. A. E. Belanger, G. S. Besra, M. E. Ford et al., "The embAB genes of Mycobacteriumaviumencode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 21, pp. 11919-11924, 1996.
12. H. Huang, M. S. Scherman, W. D'Haeze et al., "Identification and active expression of the Mycobacterium tuberculosis gene encoding 5-phospho-α-D-ribose-1-diphosphate: decaprenylphosphate 5-phosphoribosyltransferase, the first enzyme committed to decaprenylphosphoryl-D-arabinose synthesis," The Journal of Biological Chemistry, vol. 280, no. 26, pp. 24539-24543, 2005.
13. Z. Sun, J. Zhang, H. Song et al., "Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates," The International Journal of Tuberculosis and Lung Disease, vol. 14, no. 11, pp. 1436-1441, 2010.
14. H. Masur, "Recommendations on prophylaxis and therapy for disseminated Mycobacteriumaviumcomplex disease in patients infected with the human immunodeficiency virus," The New England Journal of Medicine, vol. 329, no. 12, pp. 898-904, 1993.
15. R. Moure, M. Español, G. Tudó et al., "Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array-authors' response," Journal of Antimicrobial Chemotherapy, vol. 69, no. 8, pp. 2299-2300, 2014.
16. Z. Bakuła, A. Napiórkowska, J. Bielecki, E. Augustynowicz-Kopeć, Z. Zwolska, and T. Jagielski, "Mutations in the embB gene and their association with ethambutol resistance in multidrug-resistant mycobacterium tuberculosis clinical isolates from Poland," BioMed Research International, vol. 2013, Article ID 167954, 5 pages, 2013.
17. D. Shi, L. Li, Y. Zhao et al., "Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China," Journal of Antimicrobial Chemotherapy, vol. 66, no. 10, Article ID dkr284, pp. 2240-2247, 2011.
18. J.-H. Yoon, J.-S. Nam, K.-J. Kim et al., "Molecular characterization of drug-resistant and-susceptible Mycobacterium tuberculosis isolated from patients with tuberculosis in Korea," DiagnosticMicrobiology and Infectious Disease, vol. 72, no. 1, pp. 52-61, 2012.
19. J. Perdigão, R. Macedo, A. Ribeiro, L. Brum, and I. Portugal, "Genetic characterisation of the ethambutol resistancedetermining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations," International Journal of Antimicrobial Agents, vol. 33, no. 4, pp. 334-338, 2009.
20. F. Brossier, N. Veziris, A. Aubry, V. Jarlier, and W. Sougakoff, "Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates," Journal of Clinical Microbiology, vol. 48, no. 5, pp. 1683-1689, 2010.
21. S. Srivastava, A. Ayyagari, T. N. Dhole, K. K. Nyati, and S. K. Dwivedi, "emb nucleotide polymorphisms and the role of embB306mutations inMycobacteriumtuberculosis resistance to ethambutol," International Journal ofMedicalMicrobiology, vol. 299, no. 4, pp. 269-280, 2009.
22. C. Plinke, H. S. Cox, S. Kalon, D. Doshetov, S. Rüsch-Gerdes, and S. Niemann, "Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results," Tuberculosis, vol. 89, no. 6, pp. 448-452, 2009.
23. S. V. Ramaswamy, A. G. Amin, S. Göksel et al., "Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis," Antimicrobial Agents and Chemotherapy, vol. 44, no. 2, pp. 326-336, 2000.
24. W.-L. Huang, T.-L. Chi, M.-H. Wu, and R. Jou, "Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis," Journal of Clinical Microbiology, vol. 49, no. 7, pp. 2502-2508, 2011.
25. L. I. Zhao, Q. Sun, H. C. Liu et al., "Analysis of embCAB mutations associated with ethambutol resistance in multidrugresistant Mycobacterium tuberculosis isolates from China," Antimicrobial Agents and Chemotherapy, vol. 59, no. 4, pp. 2045-2050, 2015.
26. A. M. Starks, A. Gumusboga, B. B. Plikaytis, T. M. Shinnick, and J. E. Posey, "Mutations at embB codon306 are animportant molecular indicator of ethambutol resistance in Mycobacterium tuberculosis," Antimicrobial Agents and Chemotherapy, vol. 53, no. 3, pp. 1061-1066, 2009.
27. G. P. S. Jadaun, R. Das, P. Upadhyay, D. S. Chauhan, V. D. Sharma, and V.M. Katoch, "Role of embCAB gene mutations in ethambutol resistance inMycobacterium tuberculosis isolates from India," International Journal of Antimicrobial Agents, vol. 33, no. 5, pp. 483-486, 2009.
28. R. Goude, A. G. Amin, D. Chatterjee, and T. Parish, "The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis," Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4138-4146, 2009.
29. C. U. Köser, D. K. Summers, and J. A. C. Archer, "Thr270Ile in embC (Rv3793) is not a marker for ethambutol resistance in the Mycobacteriumtuberculosis complex," Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, article 1825, 2011.
30. L. He, X. Wang, P. Cui et al., "ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis," Tuberculosis, vol. 95, no. 2, pp. 149-154, 2015.
31. H. Safi, B. Sayers, M. H. Hazbon, and D. Alland, "Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin," Antimicrobial Agents and Chemotherapy, vol. 52, no. 6, pp. 2027-2034, 2008.
32. C. Plinke, K. Walter, S. Aly, S. Ehlers, and S. Niemann, "Mycobacteriumtuberculosis embB codon 306mutations confer moderately increased resistance to ethambutol in vitro and in vivo," Antimicrobial Agents and Chemotherapy, vol. 55,no. 6, pp. 2891-2896, 2011.
33. K. Ängeby, P. Juréen, G. Kahlmeter, S. E. Hoffner, and T. Schönd, "Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis," Bulletin of theWorld Health Organization, vol. 90, no. 9, pp. 693-698, 2012.
34. X. Zhang, L. Liu, Y. Zhang, G. Dai, H. Huang, and Q. Jina, "Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012," Antimicrobial Agents and Chemotherapy, vol. 59, no. 2, pp. 1320-1324, 2015.
35. Z. Zhang, Y.Wang, Y. Pang, and K.M. Kam, "Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrugresistant Mycobacterium tuberculosis isolates," Journal of Clinical Microbiology, vol. 52, no. 2, pp. 638-641, 2014.
36. Z.Mei, Z. Sun,D. Bai et al., "Discrepancies in drug susceptibility test for tuberculosis patients resulted from the mixed infection and the testing system," BioMed Research International, vol. 2015, Article ID 651980, 7 pages, 2015.
37. M. Sareen and G. K. Khuller, "Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra,"AntimicrobialAgents and Chemotherapy, vol. 34, no. 9, pp. 1773-1776, 1990.
38. S. Ahmad, E. Mokaddas, and A.-A. Jaber, "Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations," Molecular and Cellular Probes, vol. 18, no. 5, pp. 299-306, 2004.